Dostarlimab Achieves 100% Clinical Complete Response in Rectal Cancer Trial

A recent study showed that all patients with rectal cancer in the trial experienced a clinical complete response after receiving dostarlimab in the neoadjuvant setting. Researchers administered the drug to patients before they underwent standard treatments like surgery and radiation. Specifically, the trial investigated the use of dostarlimab, an immunotherapy drug, as a neoadjuvant treatment. The study involved a small group of patients with locally advanced rectal cancer. Following dostarlimab treatment, all patients demonstrated no evidence of detectable tumor on MRI scans, endoscopies, or digital rectal exams.

Newsflash | Powered by GeneOnline AI
Date: April 28, 2025

Related posts:

The Fallout of the USAID Funding Freeze: Implications for Global Health and Biopharmaceutical Innovation New Ebola Virus Research Boosts Pandemic Preparedness AI Scribe Tool Boosts Doctor-Patient Interaction, Reduces After-Hours Work Versatile AI System from Cornell Detects Subtle Changes in Medical Imaging Series

Author

Mark Chiang

紐約 NYU Computer Science 碩士 紐澤西 UMDNJ Biomedical Informatics 博士 中研院博士後 台灣大學博士後